High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin - PubMed (original) (raw)

High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin

K W Albrecht et al. J Neurooncol. 2001 Jul.

Abstract

The value of chemotherapy in patients with malignant astrocytoma remains controversial. In our laboratories in vitro experiments with organotypic spheroid cultures showed superior effectiveness of anthracyclines. Systemic administration did not provide in therapeutic concentrations so far. Because recent studies on Daunorubicin in liposomes in the treatment of Kaposi sarcoma have shown effectiveness with diminished systemic toxicity, we administered intravenously a single dose of Daunorubicin in liposomes in eight patients at different intervals prior to surgery (12-50 h). In samples taken from tumor, tumor-edge and where possible from adjacent brain, the levels of Daunorubicin and its active metabolite Daunorubicinol were assessed with high performance liquid chromatography. Here we report that high concentrations of Daunorubicin and Daunorubicinol were found in malignant gliomas after systemic administration of liposomal Daunorubicin.

PubMed Disclaimer

Similar articles

• Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
  Zucchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. Zucchetti M, et al. Cancer Chemother Pharmacol. 1999;44(2):173-6. doi: 10.1007/s002800050964. Cancer Chemother Pharmacol. 1999. PMID: 10412954
• Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
  Cusack BJ, Young SP, Vestal RE, Olson RD. Cusack BJ, et al. Cancer Chemother Pharmacol. 1997;39(6):505-12. doi: 10.1007/s002800050606. Cancer Chemother Pharmacol. 1997. PMID: 9118462
• The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
  Fumagalli L, Zucchetti M, Parisi I, Viganò MG, Zecca B, Careddu A, D'Incalci M, Lazzarin A. Fumagalli L, et al. Cancer Chemother Pharmacol. 2000;45(6):495-501. doi: 10.1007/s002800051025. Cancer Chemother Pharmacol. 2000. PMID: 10854138 Clinical Trial.
• [Pharmacokinetics of new anthracyclines].
  Robert J. Robert J. Bull Cancer. 1988;75(2):167-74. Bull Cancer. 1988. PMID: 3282579 Review. French.
• CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
  Mayer LD, Tardi P, Louie AC. Mayer LD, et al. Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31213803 Free PMC article. Review.

Cited by

• Getting into the brain: approaches to enhance brain drug delivery.
  Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Patel MM, et al. CNS Drugs. 2009;23(1):35-58. doi: 10.2165/0023210-200923010-00003. CNS Drugs. 2009. PMID: 19062774 Review.
• Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
  Vogelbaum MA, Krivosheya D, Borghei-Razavi H, Sanai N, Weller M, Wick W, Soffietti R, Reardon DA, Aghi MK, Galanis E, Wen PY, van den Bent M, Chang S. Vogelbaum MA, et al. Neuro Oncol. 2020 Nov 26;22(11):1568-1579. doi: 10.1093/neuonc/noaa149. Neuro Oncol. 2020. PMID: 32598442 Free PMC article.
• Emerging insights into barriers to effective brain tumor therapeutics.
  Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H. Woodworth GF, et al. Front Oncol. 2014 Jul 21;4:126. doi: 10.3389/fonc.2014.00126. eCollection 2014. Front Oncol. 2014. PMID: 25101239 Free PMC article. Review.
• Lipid-Based Nanocarriers for The Treatment of Glioblastoma.
  Iturrioz-Rodríguez N, Bertorelli R, Ciofani G. Iturrioz-Rodríguez N, et al. Adv Nanobiomed Res. 2020 Nov 26;1(2):2000054. doi: 10.1002/anbr.202000054. eCollection 2021 Feb. Adv Nanobiomed Res. 2020. PMID: 33623931 Free PMC article.
• Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.
  Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Upton DH, et al. Theranostics. 2022 Jun 6;12(10):4734-4752. doi: 10.7150/thno.69682. eCollection 2022. Theranostics. 2022. PMID: 35832071 Free PMC article. Review.

References

1. 1. Br J Cancer. 1996 Jul;74(2):187-93 - PubMed
2. 1. Cancer Res. 1984 Sep;44(9):3698-705 - PubMed
3. 1. Neurosurgery. 1992 Jul;31(1):89-98; discussion 98-9 - PubMed
4. 1. Drugs. 1997 Mar;53(3):520-38 - PubMed
5. 1. J Clin Oncol. 1990 Jun;8(6):1093-100 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.